[Skip to Content]
[Skip to Content Landing]
Views 2,057
Citations 0
News From the Food and Drug Administration
November 20, 2018

Blood Group Genotyping Test Goes Beyond A, B, and O

JAMA. 2018;320(19):1970. doi:10.1001/jama.2018.17838

The FDA has approved a molecular assay that helps determine blood compatibility for transfusion patients by identifying genetic markers that code for red blood cell antigens.

The ID Core XT blood group genotyping kit can streamline blood compatibility testing and offers clinicians another alternative to antisera blood testing, Peter Marks, MD, PhD, director of the FDA’s Center for Biologics Evaluation and Research, said in a statement. “We know that DNA testing holds great promise to provide more informative, accurate, and cost-effective methods that can enhance patient care,” he noted.